ArticleCancer management and research2025
The Value of Integrating Hormone Receptors into Immunohistochemistry-Based Simplified Molecular Classification in Endometrial Cancer.
Article in Cancer management and research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Endocrine Therapy for Endometrial Carcinoma: Current Evidence, Resistance Mechanisms, and Biomarker-Driven Patient Selection.Current oncology (Toronto, Ont.) · 2026Review
- Differences in survival outcomes between HER2-low and HER2-zero breast cancer across heterogeneous HR expression patterns: a real-world study.World journal of surgical oncology · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Purpose: To explore the clinical utility of immunohistochemistry (IHC)-based molecular classification and evaluate the distribution patterns and clinical implications of hormone receptor (HR) expression across different molecular classifications in endometrial cancer (EC). Patients and Methods: This study retrospectively conducted simplified molecular classification based on IHC analysis of mismatch repair (MMR) and p53 protein from 322 EC patients admitted to the Obstetrics and Gynecology Department of Tianjin Medical University General Hospital from March 2017 to April 2024. 121 patients underwent WHO molecular classification by gene sequencing and IHC analysis. The application value of IHC-based simplified molecular classification was evaluated. The association between HR expression and molecular classification, and their combined value in predicting survival were analyzed. Results: In IHC-based simplified molecular classification, 23.3% (75/322), 59.9% (193/322), and 16.8% (54/322) patients were included in the MMR deficient (MMRd) group, MMR proficient (MMRp) group, and p53-abnormal (p53abn) group, respectively. This classification correlated significantly with various clinicopathological features such as age (p=0.001), body mass index (p=0.016), FIGO stage (p=0.002), histological subtype (p<0.001), and tumor differentiation (p<0.001). Furthermore, differences in disease-free survival (DFS) among these groups were statistically significant (p=0.002). Subgroup analyses revealed that HR expressions significantly affected DFS within molecular classification groups. Patients with positive estrogen receptor (ER) or progesterone receptor (PR) expression demonstrated better DFS than those with negative expression in these groups (ER in MMRp: p<0.001, PR in MMRp: p<0.001, ER in MMRd: p<0.001, PR in MMRd: p=0.032, ER in p53abn: p=0.052, PR in p53abn: p=0.019). Conclusion: IHC-based simplified molecular classification is an economically viable and clinically applicable method that effectively stratifies patients by clinicopathological features and prognosis. Moreover, this approach allows stratification into different prognostic risk groups based on HR expression in molecular classification subgroups.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.